Rheumatoid arthritis proof-of-concept results
Company-hosted report describing the Citruslabs-managed single-group study, design context and reported outcomes.
Source report; not a peer-reviewed publication.
Raphael Pharmaceutical
Publications & Articles
Evidence & publications
Publications and source records.
Explore Raphael’s publications and research sources, with direct links to the original records.
Clinical study: source reports & media coverage
Open source record
Science Data Updates
Raphael’s legacy update lists Week 4 pain, daily-life, sleep, relaxation and DAS28 measures, with its own source context.
Company-posted update.
Citruslabs announcement
Raphael’s Science Data Updates lists a separate Citruslabs announcement. The original social post and its metadata require direct verification; it is not independent clinical evidence.
Open the company source listing; original announcement verification pending.
Stock Titan coverage of the proof-of-concept announcement
External coverage repeats company-reported study facts. It is retained as a linked media record, not independent clinical validation.
External coverage; source reporting remains the underlying company disclosure.
Other scientific publications & research records
The Immunopathology of COVID-19 and the Cannabis Paradigm
Scholarly review of immunopathology and cannabinoid research. It does not establish clinical efficacy for RaphaWell.
DOI: 10.3389/fimmu.2021.631233. Original company-hosted PDF ↗
High-CBD Extract (CBD-X) in Asthma Management: Reducing Th2-Driven Cytokine Secretion and Neutrophil/Eosinophil Activity
Research on CBD-X and inflammatory mechanisms in asthma. This preparation and research context are distinct from the commercial RaphaWell product.
DOI: 10.3390/ph17101382. Original company-hosted PDF ↗
High-CBD Extract (CBD-X) Downregulates Cytokine Storm Systemically and Locally in Inflamed Lungs
Frontiers in Immunology, Volume 13. The legacy site connects this publication to Raphael’s chronic-inflammation research history.
DOI: 10.3389/fimmu.2022.875546.
High CBD extract (CBD-X) modulates inflammation and immune cell activity in rheumatoid arthritis
Miran Aswad, Antonina Pechkovsky, Narmeen Ghanayiem, Haya Hamza and Igal Louria-Hayon. Frontiers in Immunology, 16:1599109. Ex-vivo immune-cell experiments and mouse arthritis models; separate from the 12-person proof-of-concept study.
DOI: 10.3389/fimmu.2025.1599109. Original company-hosted PDF
Acute Effects of Cannabigerol on Anxiety, Stress, and Mood: A Double-Blind, Placebo-Controlled, Crossover, Field Trial
Independent study in healthy adults, separate from Raphael’s rheumatoid-arthritis research and the commercial RaphaWell product.
DOI: 10.1038/s41598-024-66879-0. Read the original methods and limitations. Original company-hosted PDF
Effect of Cannabigerol on Sleep and Quality of Life in Veterans: A Decentralized, Randomized, Placebo-Controlled Trial
A randomized, placebo-controlled research report involving veterans. This version is a preprint and has not been peer reviewed; it is not evidence about the commercial RaphaWell product.
DOI: 10.1101/2023.08.31.23294611. Read the original methods and limitations. Original company-hosted PDF
Hepatotoxicity Evaluation of Cannabidiol, Cannabinol, Cannabichromene and Cannabigerol Using a Human Quad Culture Liver Chip
Research using a human liver-chip model. Laboratory observations do not establish clinical safety or efficacy for RaphaWell.
DOI: 10.1038/s41598-025-12846-2. Read the original methods and limitations. Original company-hosted PDF
A Clinical Study to Assess the Efficacy of Cannabinoid Based Formula in Patients with Active Rheumatoid Arthritis
Citruslabs Research Team report, sponsored by Raphael Pharmaceutical. The 14-page report describes 12 adults in a single-group, eight-week study; no control group is identified. No statistically significant blood-biomarker changes were reported.
Company-sponsored research report, not a peer-reviewed publication.
Cannabigerol (CBG) Modulates Neutrophil Activity and Ameliorates Rheumatoid Arthritis Pathogenesis
Miran Aswad, Antonina Pechkovsky, Haya Hamza and Igal Louria-Hayon. Pharmaceuticals, 19(4):560. Human neutrophil experiments and a mouse arthritis model explore CBG biology; further validation is required before therapeutic positioning.
DOI: 10.3390/ph19040560. This is not the 12-person clinical study. Legacy linked PDF